ID   TK [Human B-cell lymphoma]
AC   CVCL_3216
SY   Tk
DR   CLO; CLO_0037066
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_3216
DR   Cell_Model_Passport; SIDM00323
DR   Cosmic-CLP; 1331045
DR   DepMap; ACH-002313
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1331045
DR   GEO; GSM827272
DR   GEO; GSM1670544
DR   JCRB; JCRB0157
DR   JCRB; NIHS0245
DR   LINCS_LDP; LCL-1953
DR   PharmacoDB; TK_1596_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3216
DR   Wikidata; Q54972513
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10354143;
RX   PubMed=20215515;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 5.3 days (PubMed=10354143); 30-40 hours (Note=Lot 08032007) (JCRB=JCRB0157).
CC   HLA typing: A*02:06,02:06; B*52:01,52:01; C*12:02,12:02; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Asp (c.540G>T); ClinVar=VCV001521256; Zygosity=Unspecified (PubMed=10354143).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.67%; Native American=0%; East Asian, North=79.08%; East Asian, South=19.03%; South Asian=0.83%; European, North=0.39%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0245; true.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 8
ST   D16S539: 9,11
ST   D5S818: 10,12
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C3457; B-cell non-Hodgkin lymphoma
DI   ORDO; Orphanet_171915; B-cell non-Hodgkin lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=10354143; DOI=10.1046/j.1365-2141.1999.01402.x;
RA   Yamaguchi H., Inokuchi K., Hanawa H., Tanosaki S., Shinozawa I.,
RA   Matuoka H., Dan K.;
RT   "Establishment of a near-triploid human B-cell lymphoma cell line with
RT   t(14;18) and a p53 gene point mutation.";
RL   Br. J. Haematol. 105:764-767(1999).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//